AbbVie
AbbVie’s experimental cancer drug hits wall in clinical study
April 20, 2017Research and Development AbbVie, AstraZeneca
AbbVie have released that two Phase 3 trials of its experimental cancer drug, veliparib, missed both of their primary endpoints. …
UK High Court rules against AbbVie’s Humira patents
March 6, 2017Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar
The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …
NICE rejects AbbVie’s leukaemia drug
February 16, 2017Sales and Marketing AbbVie
NICE has rejected AbbVie Venclyxto (venetoclax) for the treatment of chronic lymphocytic leukmaemia, on various grounds but primarily focusing upon …
Major pharma firms join Liverpool Uni in £14m pharmacovigilance project
January 30, 2017Research and Development, Sales and Marketing AZ, AbbVie, Eli Lilly, GSK, University of Liverpool, pharmacovigilance
The UK’s University of Liverpool is to launch a £14 million pharmacovigilance project focused on using new modelling approaches to …
Amgen drug pair become first Humira biosimilars to win EU approval
January 30, 2017Sales and Marketing AbbVie, Amgen, Amgevita, Humira, Solymbic, rheumatoid arthritis
Good news for Amgen as its two biosimilar versions of AbbVie’s blockbuster rheumatoid arthritis (RA) drug Humira (adalimumab) have been …
NICE approves Imbruvica for second-line leukaemia treatment
January 26, 2017Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica
NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …
EMA Accelerated Assessment for AbbVie’s hepatitis C regimen
January 24, 2017Manufacturing and Production, Research and Development AbbVie, EMA, hepatitis C
AbbVie has announced that its investigational, pan-genotypic regimen of Glecaprevir/Pibrentasvir has been awarded Accelerated Assessment by the European Medicines Agency …
European thumbs up for Abbvie leukaemia drug
December 8, 2016Medical Communications, Sales and Marketing AbbVie, Venclyxto
Abbvie has confirmed its Venclyxto (venetoclax) has been granted marketing authorisation by the European Commission (EC) as a monotherapy for …
Janssen reveals positive results from longest follow-up of Imbruvica
December 7, 2016Research and Development AbbVie, Cilag, Janssen, Pharmacyclics, imbruvica
Janssen used the 5th Annual American Society of Hematoly Meeting and Exposition to reveal that a five-year study of Imbruvica …
Humira biosimilar proves efficacy in Phase 3 trial
November 30, 2016Research and Development AbbVie, Amgen, FDA, Humira, M923, Momenta
US-based biotechnology firm Momenta Pharmaceuticals has announced that its biosimilar version of Abbvie’s autoimmune drug Humira (adalimumab) – currently the …
AbbVie investigational hep C drug boasts 97.5% response rate
November 15, 2016Manufacturing and Production, Medical Communications, Research and Development AbbVie, hepatitis C, pan-genotypic
AbbVie released details on their latest trials for their investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530). In an eight week …
Coherus knocked back by AbbVie’s Humira patent protection
November 8, 2016Manufacturing and Production, Sales and Marketing AbbVie, Coherus, Humira
Coherus Biosciences, a developer of biosimilars, has suffered a blow in their petition for Inter Partes Review (IPR) of one …
Tesaro’s ovarian cancer drug success threatens market rivals
October 12, 2016Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …
J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial
October 3, 2016Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab
Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque …
AbbVie opens its $300 million manufacturing plant in Singapore
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Asia, Singapore
AbbVie’s new Singapore based manufacturing plant is expected to be fully operational by late 2018. The plant is expected to …
Latest content
